Spotlight on GPP Spotlight on GPP Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
Disentangling fibrosis Disentangling fibrosis Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
IPF why wait? IPF why wait? IPF is a progressive and life threatening lung disease that can cause permanent damage in the lungs right from the start. Early diagnosis and treatment of IPF is critical, because acting quickly can make a difference.
New indications NexGard, NexGard SPECTRA and Broadline New indications NexGard, NexGard SPECTRA and Broadline New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA
It’s Your Heart. Protect It. The Podcast. It’s Your Heart. Protect It. The Podcast. In season 2, we hear from a range of experts to explore further how the interconnected systems call for collaboration and approach to care.
Bridging the gap in Generalized Pustular Psoriasis (GPP) Bridging the gap in Generalized Pustular Psoriasis (GPP) Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, discusses published insights from GPP patients.
Facing Pulmonary Fibrosis Facing Pulmonary Fibrosis Steve Jones talks about his experience facing his pulmonary fibrosis diagnosis.
collaboration criving innovation collaboration criving innovation In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
Boehringer Ingelheim half-year results 2023 Boehringer Ingelheim half-year results 2023 First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
Shared science for the best cat diabetes management Shared science for the best cat diabetes management Diabetes mellitus is a common endocrine disease with increasing prevalence in dogs and cats. Learn how science's made management easier.
CHMP_opinion_nintedanib_ILD_PF CHMP_opinion_nintedanib_ILD_PF Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Spesolimab meets key endpoint for GPP flare prevention Spesolimab meets key endpoint for GPP flare prevention Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares
Odile Bain Memorial Prize 2021 Odile Bain Memorial Prize 2021 Brilliant early-career scientists in parasitology recognized
Boehringer Ingelheim 2022 half year results Boehringer Ingelheim 2022 half year results First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
New exchange platform with Harbin Research Institute New exchange platform with Harbin Research Institute Boehringer Ingelheim and Harbin Veterinary Research Institute set up ‘industry-academia-research’ exchange platform
Pioneering for progress in generalized pustular psoriasis Pioneering for progress in generalized pustular psoriasis An event, bringing together 170 delegates from across the world to strive for excellence in care of GPP
vaxxitek® hvt + ibd + nd vaxxitek® hvt + ibd + nd Bursal Disease-Marek's disease-Newcastle disease vaccine, serotype 3, live Marek's disease vector; the vaccine includes a diluent
The generalized pustular psoriasis (GPP) Forum 2023 The generalized pustular psoriasis (GPP) Forum 2023 An executive summary of the activities and key takeaways from the GPP Forum 2023
All hands-on deck to fight the ‘zombie’ rabies virus All hands-on deck to fight the ‘zombie’ rabies virus We’re teaming up with communities and governments across Southeast Asia to fight rabies through vaccinations, education programs, and partnerships.
Boehringer expands production site in Greece Boehringer expands production site in Greece Boehringer expands production site in Greece for new medicine
Boehringer Ingelheim leader in hatchery vaccination Boehringer Ingelheim leader in hatchery vaccination Boehringer Ingelheim is a leader in hatchery vaccination with vector vaccines.
Patient Organizations Patient Organizations Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Digital solution for individualized diabetes care Digital solution for individualized diabetes care With Exandra™, we have developed a clinical decision support tool for diabetes care to make everyday life easier for healthcare professionals.